1. National Institute for Health and Care Excellence (NICE). Guide to the methods of technology appraisal 2013—process and methods [PMG9]. London: NICE. 2013. https://www.nice.org.uk/article/pmg9/ . Accessed 23 November 2016.
2. Pandor A, Stevenson M, Martyn-St James M, Stevens J, Hamilton J, Rawdin A et al. Ponatinib for treating acute lymphoblastic leukaemia: a single technology appraisal. School of Health and Related Research (ScHARR). 2016. https://www.nice.org.uk/guidance/ta451/documents/committee-papers . Accessed 20 Nov 2017.
3. National Institute for Health and Care Excellence. Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia. Final Scope. National Institute for Health and Care Excellence (NICE), London. 2016. https://www.nice.org.uk/guidance/ta451/documents/committee-papers . Accessed 20 Nov 2017.
4. Alvarnas JC, Brown PA, Aoun P, Ballen KK, Bellam N, Blum W, et al. Acute lymphoblastic leukemia. J Natl Compr Canc Netw. 2012;10(7):858–914.
5. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia. Version 1.0. 2016. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp . Accessed 23 Nov 2016.